Muscarinic antagonists (long-acting / LAMAs)
- Long-acting inhaled muscarinic blockade
- Reduce bronchoconstriction + mucus
- COPD maintenance cornerstone
- Add-on option in selected uncontrolled asthma
- Dry mouth/urinary retention can occur
- Not rescue bronchodilators
Class at a glance
- Long-acting inhaled muscarinic blockade
Practical pearls
- Reduce bronchoconstriction + mucus
- COPD maintenance cornerstone
Other practical pearls
- Add-on option in selected uncontrolled asthma
Clinical pearls
- Dry mouth/urinary retention can occur
- Not rescue bronchodilators
Pearls
- Caution: narrow-angle glaucoma, prostatic hypertrophy, bladder-neck obstruction
- Cardiovascular harm not confirmed in randomized trials
Self-check
- What do Muscarinic antagonists (long-acting / LAMAs) primarily reduce?
Bronchoconstriction + mucus. - Are LAMAs rescue bronchodilators?
No.
Drugs in this class (4)
Muscarinic antagonists (long-acting / LAMAs) prescription history
Animated chart of estimated U.S. prescriptions per year, Asthma/COPD meds (1924–2026). Inhaled antimuscarinics highlighted from 1987.
All drug classes · Open Muscarinic antagonists (long-acting / LAMAs) in the interactive console ↗